瑞派替尼治疗晚期胃肠间质瘤的研究进展  

Research Progress of Ripretinib in Treatment of Advanced Gastrointestinal Stromal Tumor

作　　者：徐晨 李岩峰[1] 曲宏岩[1] XU Chen;LI Yanfeng;QU Hongyan(Harbin Medical University Cancer Hospital,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院,黑龙江哈尔滨150081

出　　处：《肿瘤学杂志》2023年第8期714-719,共6页Journal of Chinese Oncology

摘　　要：胃肠间质瘤是一类起源于胃肠道间叶组织的肿瘤,具有复杂的肿瘤异质性,酪氨酸激酶抑制剂是胃肠间质瘤全身治疗的基础药物,显著延长了晚期胃肠间质瘤患者的生存期,但由于肿瘤基因突变位点的继发性改变,使得传统酪氨酸激酶抑制剂在晚期胃肠间质瘤的治疗存在一定局限性。瑞派替尼是一种新型的酪氨酸激酶抑制剂,可以广谱抑制KIT和血小板源性生长因子受体α的突变,从而发挥抑制肿瘤增殖的作用,为晚期胃肠间质瘤患者提供了更多的治疗机会。全文根据瑞派替尼Ⅰ期、Ⅲ期临床试验进展以及最新指南研究,就瑞派替尼的作用机制、疗效和临床应用进行综述。Gastrointestinal stromal tumor(GIST)is a tumor with complex heterogeneity that originates from mesenchymal tissues of the gastrointestinal tract.As the base of systemic treatment for GIST,tyrosine kinase inhibitors(TKIs)have significantly extended the survival of patients with advanced GIST.However,due to secondary changes in tumor gene mutation sites,conventional TKIs have demonstrated some limitations in the treatment of advanced GIST.Ripretinib is a novel TKI that inhibits tumor proliferation by extensively inhibiting mutations of KIT and platelet-derived growth factor receptorα,thus providing more therapeutic options for patients with advanced GIST.This article reviews the mechanism of action,efficacy and clinical application of ripretinib based on advances in phaseⅠand phaseⅢclinical trials of ripretinib and relevant studies included in the latest guidelines.

关 键 词：瑞派替尼 胃肠间质瘤 KIT/PDGFRα突变 研究进展 

分 类 号：R735.2[医药卫生—肿瘤]